General surgery

PRESBYTERIAN HEALTH PLAN AND NEW MEXICO ONCOLOGY HEMATOLOGY CONSULTANTS PARTNER ON NEW CONTRACT TO EXPAND ACCESS TO CARE

Retrieved on: 
Tuesday, April 16, 2024
Rheumatology, ENT, Patient, Insurance, Travel, PHP, Urology, General surgery, Nursing

ALBUQUERQUE, N.M. , April 16, 2024 /PRNewswire/ -- Presbyterian Health Plan (PHP) and New Mexico Oncology Hematology Consultants Ltd. (NMOHC) are pleased to announce a new contract effective April 1, 2024, that expands access to care for oncology patients and those seeking specialty services in New Mexico.

Key Points: 
  • ALBUQUERQUE, N.M. , April 16, 2024 /PRNewswire/ -- Presbyterian Health Plan (PHP) and New Mexico Oncology Hematology Consultants Ltd. (NMOHC) are pleased to announce a new contract effective April 1, 2024, that expands access to care for oncology patients and those seeking specialty services in New Mexico.
  • This agreement eliminates the need for NMOHC patients with PHP insurance to travel to other locations for covered services.
  • "This improved access allows patients to receive essential care more conveniently," explains Dr. Barbara McAneny, CEO of New Mexico Oncology Hematology Consultants Ltd. "Our comprehensive practice offers a wide range of services, including oncology, pulmonology, urology, ENT, rheumatology, and general surgery, all under one roof."
  • "We have worked closely with NMOHC on a contract solution that we think benefits the people we jointly serve," said Brandon Fryar, president of Presbyterian Health Plan.

Esteemed Los Angeles Cosmetic and Reconstructive Surgeon Dr. Farzin Kerendian Honored as a Top Patient Rated Doctor for 2024 by Find Local Doctors

Retrieved on: 
Tuesday, April 9, 2024
Health, Elective surgery, Male, Patient, Lip, Doctor, Blepharoplasty, General surgery, Physician, Beauty, LOS

LOS ANGELES, April 9, 2024 /PRNewswire-PRWeb/ -- Dr. Farzin Kerendian, a board-certified cosmetic and reconstructive surgeon, has once again been recognized with the esteemed accolade of a Top Patient Rated Doctor for the year 2024 by Find Local Doctors. Operating out of his cutting-edge clinic, Desired Beauty, Dr. Kerendian employs state-of-the-art technology and unparalleled artistry to deliver transformative results tailored to each individual's desires. This prestigious recognition from Find Local Doctors underscores Dr. Kerendian's consistent receipt of five-star ratings and glowing patient testimonials, solidifying his status as a trusted expert in the field. Find Local Doctors, a user-friendly online directory, connects consumers with skilled physicians renowned for their expertise, making it easier for individuals to access top-tier healthcare professionals in their area.

Key Points: 
  • LOS ANGELES, April 9, 2024 /PRNewswire-PRWeb/ -- Dr. Farzin Kerendian, a board-certified cosmetic and reconstructive surgeon , has once again been recognized with the esteemed accolade of a Top Patient Rated Doctor for the year 2024 by Find Local Doctors .
  • Operating out of his cutting-edge clinic, Desired Beauty, Dr. Kerendian employs state-of-the-art technology and unparalleled artistry to deliver transformative results tailored to each individual's desires.
  • My mission has always been to empower my patients and help them achieve their beauty aspirations," states Dr. Farzin Kerendian.
  • My mission has always been to empower my patients and help them achieve their beauty aspirations," states Dr. Farzin Kerendian.

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

Retrieved on: 
Monday, April 8, 2024
Surgeon, Plastic, Associate, Education, Matrix, National Cancer Institute, Bellevue Hospital, MD Anderson Cancer Center, NYU, University, General surgery, Surgical oncology, Health, FACS, Dentistry

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.

Key Points: 
  • MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.
  • Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems.
  • “With more than 30 years of experience in plastic and reconstructive surgery, I understand the needs and challenges in this space,” said Dr. Langstein.
  • "We are thrilled to welcome Dr. Langstein to our team," said Paul Talmo, Chief Technology Officer of TELA Bio.

Sutter Health Announces Significant Investment in a New Advanced Multi-Specialty Neurosciences Care Complex in San Francisco’s Mission Neighborhood

Retrieved on: 
Thursday, April 4, 2024
Neurology, Diagnosis, Brain, Cardiology, Partnership, Physician, Health, Patient, SAN, Stroke, Research, Aneurysm, Elective surgery, Sutter Health, General surgery, Forbes Norris, Neurosurgery, Investment, Pediatrics, Hospital, Endocrinology, Podiatry, Graduate medical education, Rehabilitation, Nursing

The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.

Key Points: 
  • The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.
  • Finally, Sutter will expand primary care and women’s care services on the Mission Bernal Campus at the Monteagle building ( 1580 Valencia St .).
  • "At Sutter Health, the commitment to expanding access to high-quality care is unstoppable,” said Ken McNeely, Sutter Health board chair.
  • “This investment underscores the organization's dedication to meeting the health care needs of Northern California communities, ensuring that patients receive exceptional care close to home.

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Flex, Growth, Urology, Communication, Patient, Telephone, Sale, TRUST, General surgery, Software, Security (finance), Motion, Freezing, LUNA, Surgeon, Bank statement, Gynaecology, Investment, Annual report, Triangle Park (Quezon City), GAAP, File, Optimism, FDA, CIS, Health, Nursing

“As we look at 2024, there's a sense of optimism as we aim to hit significant milestones in the coming quarters.

Key Points: 
  • “As we look at 2024, there's a sense of optimism as we aim to hit significant milestones in the coming quarters.
  • During the fourth quarter of 2023, the Company initiated five new Senhance Surgical System placements, one in Germany, one in Romania, two in the CIS region and one in Japan at Nagoya University Hospital.
  • In 2023, surgeons performed over 3,550 procedures utilizing the Senhance System, representing a 13% increase over the previous year.
  • In addition to regulatory milestones, the Company has introduced four Senhance System programs dedicated to pediatric departments in the U.S. and internationally.

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Thursday, March 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Thursday, March 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

Penn Highlands Healthcare Doctors Beyond the Borders

Retrieved on: 
Wednesday, March 20, 2024
MSUCOM, Famine, Forward surgical teams, Osteopathy, Hamas, The, Clinical professor, Patient, Trauma, Sports medicine, Medical director, Nursing, Research, Orthopedic surgery, Education, Samaritan's Purse, Woman, Water quality, General surgery, Emergency medicine, Injury, FACS, Altitude, EVP, Disease, Hospital, Poverty, Family, DOCARE, Universidad, Global Health, Firefighter, Physician, International health, Medicine

Penn Highlands Healthcare offers 849 physicians who provide a wide range of care and treatments at locations throughout 26 counties in Pennsylvania.

Key Points: 
  • Penn Highlands Healthcare offers 849 physicians who provide a wide range of care and treatments at locations throughout 26 counties in Pennsylvania.
  • Penn Highlands Healthcare physicians can be found in the health system’s eight hospitals as well as many community medical buildings, outpatient facilities, surgery centers and physician practices.
  • Some Penn Highlands Healthcare physicians do not allow county, state or continental borders to keep them from providing care where it is needed.
  • Dr. Sergent, who is an emergency medicine physician and the Central Region Medical Director of Emergency Medicine at Penn Highlands Healthcare, shares his skills and expertise beyond the U.S. borders in Central and South America.

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Retrieved on: 
Tuesday, March 12, 2024
Mallinckrodt, Cirrhosis, Patient, Korran, King Edward Medical University, Drug, Galectin, General surgery, Therapy, Cancer, GALT, Nursing care plan, NASH, Poster, Pharmaceutical industry

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D.

Key Points: 
  • NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D.
  • as Vice President, Clinical Development.
  • Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry.
  • “We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program” said Pol F. Boudes, M.D., Chief Medical Officer.

Research: Surgeons, Hospitals Involved in Exceptional Research Have Lower Patient Mortality Rates, Fewer Complications

Retrieved on: 
Wednesday, April 3, 2024
Software, Research, Oncology, Technology, Hospitals, Health Technology, Science, Surgery, Cardiology, Neurology, Practice Management, Health, JAMA, Evidence-based medicine, Surgeon, Urology, Environment, Physician, Impact factor, Hospital, Mortality, Patient, General surgery, Neurosurgery, Ear, Woman, Otorhinolaryngology, Male, Publication, Novant Health, Harvard Business Review, Nose, Surgical oncology, Medicare, PubMed, Elective surgery, Gastroenterology

Surgeons and hospitals who conduct the most leading-edge research achieve lower rates of patient mortality and complications than those who do not, according to findings released today by Avant-garde Health.

Key Points: 
  • Surgeons and hospitals who conduct the most leading-edge research achieve lower rates of patient mortality and complications than those who do not, according to findings released today by Avant-garde Health.
  • Patients under the care of top surgeon-researchers showed a 5% lower rate of post-discharge complications and a 5% lower rate of mortality, within 30 days post-discharge, according to the research.
  • All 4,500 physicians and 350 hospitals being honored are listed on the Research All-Stars site .
  • In addition, a significant portion of the top surgeon-researchers – 47.1% on average – served as the leading or senior authors of their research.